| A living WHO guideline on drugs for covid-19 A Agarwal, B Rochwerg, F Lamontagne, RAC Siemieniuk, T Agoritsas, ... | 944 | 2022 |
| Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries H Getahun, A Matteelli, I Abubakar, MA Aziz, A Baddeley, D Barreira, ... European Respiratory Journal 46 (6), 1563-1576, 2015 | 711 | 2015 |
| Corona virus disease 2019 D Handayani, DR Hadi, F Isbaniah, E Burhan, H Agustin Jurnal Respirologi Indonesia 40 (2), 119-129, 2020 | 372 | 2020 |
| Pedoman nasional pengendalian tuberkulosis RI Kemenkes Jakarta: kementerian kesehatan RI, 2014 | 352 | 2014 |
| Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study H Surendra, IRF Elyazar, BA Djaafara, LL Ekawati, K Saraswati, V Adrian, ... The Lancet Regional Health–Western Pacific 9, 2021 | 214 | 2021 |
| Pedoman tatalaksana COVID-19 E Burhan | 201 | 2020 |
| Pneumonia covid-19 diagnosis & penatalaksanaan di Indonesia E Burhan, F Isbaniah, AD Susanto, Y Yoga, A Tjandra, T Sugiri, ... Jakarta: Perhimpunan Dokter Paru Indonesia, 1-49, 2020 | 170 | 2020 |
| Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial IH Dilogo, D Aditianingsih, A Sugiarto, E Burhan, T Damayanti, ... Stem cells translational medicine 10 (9), 1279-1287, 2021 | 136 | 2021 |
| A living WHO guideline on drugs to prevent covid-19 F Lamontagne, M Stegemann, A Agarwal, T Agoritsas, R Siemieniuk, ... bmj 372, 2021 | 135 | 2021 |
| A living WHO guideline on drugs for covid-19 R Siemieniuk, B Rochwerg, T Agoritsas, F Lamontagne, YS Leo, ... BMJ: British Medical Journal 370, 1-14, 2020 | 121 | 2020 |
| Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial South East Asia Infectious Disease Clinical Research Network Bmj 346, 2013 | 121 | 2013 |
| Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients E Burhan, C Ruesen, R Ruslami, A Ginanjar, H Mangunnegoro, ... Antimicrobial agents and chemotherapy 57 (8), 3614-3619, 2013 | 119 | 2013 |
| Pedoman tatalaksana COVID-19 edisi 3 E Burhan, AD Susanto, SA Nasution, E Ginanjar, CW Pitoyo, A Susilo, ... Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI 2 (1), 2020 | 99 | 2020 |
| Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia FA Putri, E Burhan, A Nawas, PZ Soepandi, DK Sutoyo, H Agustin, ... The International journal of tuberculosis and lung disease 18 (5), 564-570, 2014 | 89 | 2014 |
| Molecular diagnosis of tuberculosis F Nurwidya, D Handayani, E Burhan, F Yunus Chonnam medical journal 54 (1), 1, 2018 | 85 | 2018 |
| COVID‑19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study ICCG 1062 ISARIC Clinical Characterisation Group 49, 889-905, 2021 | 81* | 2021 |
| Effects of introducing Xpert MTB/RIF on diagnosis and treatment of drug-resistant tuberculosis patients in Indonesia: a pre-post intervention study SC Van Kampen, NH Susanto, S Simon, SD Astiti, R Chandra, E Burhan, ... PloS one 10 (6), e0123536, 2015 | 81 | 2015 |
| Pedoman pencegahan dan pengendalian Coronavirus Disease (COVID-19) A Sugihantono, E Burhan, AD Susanto, T Damayanti, WH Wiyono, ... Jakarta Selatan: Kemenkes RI, 2020 | 76 | 2020 |
| Treatment strategy for rifampin-susceptible tuberculosis NI Paton, C Cousins, C Suresh, E Burhan, KL Chew, VB Dalay, Q Lu, ... New England Journal of Medicine 388 (10), 873-887, 2023 | 66 | 2023 |
| Protokol tatalaksana COVID-19 E Burhan, AD Susanto, SA Nasution, E Ginanjar, CW Pitoyo, A Susilo, ... Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI 50, 2020 | 60 | 2020 |
